Tests radiofrequency field treatment with chemoradiation for brain tumor glioblastoma
Tests a radiofrequency field device with radiation and chemotherapy in adults with glioblastoma.
Plain-language title generated from the registry record
Registry title: Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With Radiochemotherapy and Maintenance Chemotherapy in Patients With Glioblastoma (Brain-RF)
Key facts
- Where
- Berlin, GermanySee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT06140875, who can take part
Where in Germany
- Charité Universitätsmedizin BerlinBerlin, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Charite University, Berlin, Germany
- Trial code
- NCT06140875
- Record updated
- 13 February 2025
- Original description
Combined chemoradiation and radiofrequency electromagnetic field treatment for patients with glioblastomaRead full original descriptionShow less
Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With Radiochemotherapy and Maintenance Chemotherapy in Patients With Glioblastoma (Brain-RF)
Combined chemoradiation and radiofrequency electromagnetic field treatment for patients with glioblastoma
Inclusion: Pathological evidence of newly diagnosed glioblastoma according to WHO classification criteria; Patients 18 to 70 years of age with a WHO performance status of 2 or less; All patients must sign written informed consent; Adequate hematologic, renal, and hepatic function (absolute neutrophil count, ≥1,5 x 103/μL; platelet count, ≥100 x 103/μL; serum creatinine ≤1.7 mg/dL; total bilirubin > upper limit of normal; AST or ALT ≤3 times the upper limit of normal); Patient must have received subtotal or gross total resection of the tumor; MGMT-promotor methylated patients must have refused therapy according to the CeTeG/NOA-09 protocol (+ Lomustin); Patient must be planned for concomitant RCT with a total RT dose of 60 Gy over six weeks and temozolomide followed by six cycles of maintenance CT using temozolomide.
Exclusion: Previous cranial RT; Technical impossibility to use AM-RF-EMF (pacemaker, defibrillator or deep brain stimulator, metal implants); Cytostatic therapy / anti-angiogenic substances / CT or radiation therapy for cancer within the past 5 years; History of cancers or other comorbidities that limit life expectancy to less than five years; Technical impossibility to use magnetic resonance imaging (MRI) or known allergies against MRI and/or computed tomography (CT) contrast agents; Participants of childbearing age unwilling to use or not capable of using effective contraception; Postoperative evidence of increased intracranial pressure (midline shift > 5mm, clinically significant papilledema, vomiting and nausea or reduced level of consciousness); Pregnant patients.